1. Evaluating the likelihood to be helped or harmed after treatment with viloxazine extended‐release in children and adolescents with attention‐deficit/hyperactivity disorder. Issue 8 (26th May 2021) Authors: Nasser, Azmi; Kosheleff, Alisa R.; Hull, Joseph T.; Liranso, Tesfaye; Qin, Peibing; Busse, Gregory D.; Fava, Maurizio; Maletic, Vladimir; Rubin, Jonathan; Lopez, Frank Journal: International journal of clinical practice Issue: Volume 75:Issue 8(2021) Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Impact of Paroxetine, a Strong CYP2D6 Inhibitor, on SPN‐812 (Viloxazine Extended‐Release) Pharmacokinetics in Healthy Adults. Issue 11 (4th May 2021) Authors: Wang, Zhao; Kosheleff, Alisa R.; Adeojo, Lilian W.; Odebo, Oyinkansola; Adewole, Toyin; Qin, Peibing; Maletic, Vladimir; Schwabe, Stefan; Nasser, Azmi Journal: Clinical pharmacology in drug development Issue: Volume 10:Issue 11(2021) Page Start: 1365 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Impact of Viloxazine Extended-Release Capsules (Qelbree®) on Executive Function in Adults With ADHD During an Open-Label Extension Study. (April 2023) Authors: Nasser, Azmi; Hull, Joseph; Yarullina, Ilmiya; Qin, Peibing; Rubin, Jonathan Journal: CNS spectrums Issue: Volume 28:Number 2(2023) Page Start: 218 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗